Rani Therapeutics Holdings, Inc. RANI

RANI Company Overview

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) is a clinical-stage biotechnology company focused on developing technologies that enable the oral delivery of biologic drugs traditionally administered by injection. The company operates within the biopharmaceutical, drug delivery, and medical device industries, with its core platform centered on the proprietary RaniPill® capsule technology. The platform is designed to deliver biologics, including peptides, proteins, and antibodies, directly into the intestinal wall using an ingestible capsule mechanism intended to improve patient convenience and adherence. Revenue generation has historically been limited because the company remains in the clinical development stage, with funding primarily derived from equity financing, strategic collaborations, and research partnerships.

Rani Therapeutics was founded in 2012 by serial entrepreneur and inventor Mir Imran, who has founded multiple medical technology and healthcare companies. Since inception, the company has evolved from an early-stage device innovator into a biotechnology platform company pursuing oral biologic therapeutics across several disease categories, including inflammatory, metabolic, and endocrine disorders. Its strategic positioning is based on the potential to replace injectable biologics with orally administered alternatives while leveraging partnerships with pharmaceutical companies interested in extending biologic drug delivery capabilities.